Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic fatigue syndrome (CFS) is a devastating and complex disorder. People with CFS experience overwhelming fatigue and a host of other symptoms that are not improved by bed rest. Interestingly, many of the symptoms experienced by people with CFS are identical to symptoms caused by long-term low-level exposure to mercury, which is called micromercurialism.

This study will examine if the mercury binding substance IodoCarb(r) can improve the health of patients with CFS.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PharmaLundensis AB
• Treatments: Charcoal

Criteria

Inclusion Criteria:

• Chronic fatigue syndrome

• 35-60 years old

• Male

• Female (not pregnant or breastfeeding, using adequate highly effective contraception consistently and correctly or >1 year post-menopausal or surgically sterile).

Exclusion Criteria:

• Iodine allergy

• abnormal thyroid function or other thyroid disease such as goiter

• severely reduced kidney function (Cystatin C > 1.5 mg/L)

• alcohol/drug abuse

• severe depression

• severe fibromyalgia

• severe cardio-vascular disease

• other severe disease, according to the clinical investigator

• participation in another ongoing clinical trial

• participation in drug trial the preceding 3 months